Effects of cholinergic drugs and cognitive training on dementia

Dementia and Geriatric Cognitive Disorders

Volumn 18, Issue 1, 2004, Pages 50-54

  Requena, C ^a   Lopez Ibor M I ^b   Maestu F ^b   Campo, P ^b   Lopez Ibor J J ^b   Ortiz, T ^b  

^a UNIVERSITY OF LEÓN   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Alzheimer's disease; Cognitive therapy; Donepezil

Indexed keywords

CHOLINERGIC RECEPTOR STIMULATING AGENT; DONEPEZIL;

ACADEMIC ACHIEVEMENT; AFFECT; AGED; ARTICLE; CLINICAL TRIAL; COGNITION; COGNITIVE THERAPY; DEMENTIA; DEPRESSION; DETERIORATION; DRUG EFFECT; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MUSIC THERAPY; PRIORITY JOURNAL; RATING SCALE; TRAINING; TREATMENT OUTCOME;

AGED; AGING; ALZHEIMER DISEASE; CHOLINERGIC AGENTS; COGNITION; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; DEMENTIA; FEMALE; HUMANS; INDANS; LONG-TERM CARE; MALE; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; PIPERIDINES; SEX CHARACTERISTICS;

EID: 3042634432     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077735     Document Type: Article

References (39)

1. Aldridge D: Music therapy in dementia care. London, Kingsley, 2000.
2. Baker R, Bell S, Baker E, Gibson S, Holloway J, Pearce R, Dowling Z, Thomas P, Assey J, Wareing LA: A randomized controlled trial of the effects of multi-sensory stimulation (MSS) for people with dementia. Br J Clin Psychol 2001;40(pt 1):81-96.
3. Davis RN, Massman PJ, Doody RS: Cognitive intervention in Alzheimer disease: A randomized placebo-controlled study. Alzheimer Dis Assoc Disord 2001;15:1-9.
4. Brotons M, Martí Augé P: Musicoterapia: Una estrategia y recurso eficaz para el enfermo de Alzheimer y sus cuidadores profesionales. 18th Int Conf of Alzheimer's Disease International. Barcelona, Oct 2002, p 65.
5. Burt T: Donepezil and related cholinesterase inhibitors as mood and behavioural controlling agents. Curr Psychiatry Rep 2000;2:473-478.
6. Nobili F, Vitali P, Canfora M, Girtler N, De Leo C, Mariani G, Pupi A, Rodríguez G: Effects of long-term Donepezil therapy on rCBF of Alzheimer's patients. Clin Neurophysiol 2002;113:1241-1248.
7. Perlis ML, Smith MT, Orff HJ, Andrews PJ, Gillin JC, Giles DE: The effects of an orally administered cholinergic agonist on REM sleep in major depression. Biol Psychiatry 2002;51:457-462.
8. Rodríguez G, Vitali P, De Leo C, De Carli F, Girtler N, Nobili F: Quantitative EEG changes in Alzheimer patients during long-term donepezil therapy. Neuropsychobiology 2002;46:49-56.
9. Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, Pratt RD: A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001;57:481-488.
10. Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, Wetterholm AL, Zhang R, Haglund A, Subbiah P, the Donepezil Nordic Study Group: A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001;57:489-495.
11. Rockwood K, Graham JE, Fay S: Goal setting and attainment in Alzheimer's disease patients treated with donepezil. J Neurol Neurosurg Psychiatry 2002;73:500-507.
12. Davis RN, Massman PJ, Doody RS: Cognitive intervention in Alzheimer disease: A randomized placebo-controlled study. Alzheimer Dis Assoc Disord 2001;15:1-9.
13. Bernhardt T, Maurer K, Frolich L: Effect of daily-living-related cognitive training on attention and memory performance of persons with dementia. Z Gerontol Geriatr 2002;35:32-38.
14. Farinal E, Fioravanti R, Chiavari L, Imbornone E, Alberoni M, Pomati S, Pinardi G, Pignatti R, Mariani C: Comparing two programs of cognitive training in Alzheimer's disease: A pilot study. Acta Neurol Scand 2002;105:365-371.
15. McKhann G: New Neurons for Aging Brains. Ann Neurol 2002;52:133-134.
16. Reisberg B, Ferris SH, Anand R, De León MJ, Schneck MK, Buttinger C, Borenstein J: Functional staging of dementia of the Alzheimer's type. Ann NY Acad Sci 1982;435:481-483.
17. Yesavage JA, Brink TL, Rose TL, Lum O, Huang VS, Adey M, Leirer VO: Development and validation of a geriatric depression screening scale: A preliminary report. J Psychiatr Res 1983;17:37-39.
18. Folstein MF, Folstein SE, McHugh PR: Minimental state: A practical method for grading the mental state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
19. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
20. Corey-Bloom J, Galasko D, Thal L: Clinical features and natural history of Alzheimer's disease; in Calne DB (ed): Neurodegenerative Disease. Philadelphia, Saunders, 1993, pp 631-645.
21. Liepert J, Bauder H, Miltner WHR, Taub E, Weiller C: Treatment-induced cortical reorganization after stroke in humans. Stroke 2000;31:1210-1216.
22. Rusted JM, Marsh R, Bledski L, Sheppard L: Alzheimer patients' use of auditory and olfactory cues to aid verbal memory. Aging Ment Health 1997;1:364-371.
23. Wilson B, Moffat N: The development of group memory therapy; in Wilson B, Moffat N: Clinical Management of Memory Problems. San Diego, Singular, 1992.
24. Kaufer DI, Cummings JL, Christine D: Effect of tacrine on behavioural symptoms in Alzheimer's disease: An open-label study. J Geriatr Psychiatry Neurol 1996;9:1-6.
25. Kaufer DI, Catt K, Pollock BG, López OL, DeKosky ST: Donepezil in Alzheimer's disease - relative cognitive and neuropsychiatric responses and their relationship to caregiver distress. Neurology 1998;50(suppl 4):A89.
26. Morris JC, Cyrus PA, Orazem J, Mas J, Bieber F, Ruzicka BB, et al: Metrifonate benefits cognitive, behavioural, and global function in patients with Alzheimer's disease. Neurology 1998;50:1222-1230.
27. Raskind MA, Sadowsky CH, Sigmund WR, Beitler PJ, Auster SB: Effects of tacrine on language, praxis, and noncognitive behavioural problems in Alzheimer's disease. Arch Neurol 1997;54:836-840.
28. Weiner MF, Martin-Cook K, Foster BM, Saine K, Fontaine CS: Effects of donepezil on emotional/behavioural symptoms in Alzheimer's disease patients. J Clin Psychiatry 2000;61:487-492.
29. Bonner LT, Peskind ER: Pharmacological treatments of dementia. Med Clin North Am 2002;86:657-674.
30. Kempermann G, Gast D, Gage FH: Neuroplasticity in old age: sustained fivefold induction of hippocampal neurogenesis by long-term environmental enrichment. Ann Neurol 2002;52:135-143.
31. Van Praag H, Kempermann G, Gage FH: Neural consequences of environmental enrichment. Nat Rev Neurosci 2000;1:191-198.
32. Taub E, Uswatte G, Elbert T: New treatment in neurorehabilitation founded on basic research. Nat Rev Neurosci 2002;3:228-236.
33. Maki PM: Is implicit memory preserved in Alzheimer's disease? Implications for theories of implicit memory. Aging Cogn 1995;2:192-205.
34. Camp CJ, Foss JW, O'Hanlon AM, et al: Memory interventions for persons with dementia. Appl Cogn Psychol 1996;10:193-210.
35. Schachter DL, McAndrews, MP, Moscovitch M: Access to consciousness: Dissociations between implicit and explicit knowledge in neuropsychologic syndromes; in Weiskrantz L (ed): Thought without Language. Oxford, Clarendon Press, 1988, pp 242-278.
36. Knopman DS, Nissen MJ: Implicitit learning in patients with probable Alzheimer's disease. Neurology 1987;37:784-788.
37. Bylsma FW, Rebok G, Brandt J: Long-term retention of implicit learning in Huntington's disease. Neuropsychologia 1992;29:1213-1221.
38. Brandt J, Rich JB: Memory disorders in the dementias; in Baddeley AD, Wilson BA, Walts FN (eds): Handbook of Memory Disorders. Chichester, Wiley, 1995, pp 243-270.
39. Foldi NS, Lobosco JJ, Schaefer LA: The effect of attentional dysfunction in Alzheimer's disease: Theoretical and practical implications. Semin Speech Lang 2002;23:139-150.